Immunodeficiency virus

The viruses responsible for AIDS are human immunodeficiency virus 1 and 2 (HIV 1 and HIV 2) Both are retroviruses, meaning that their genetic material is RNA rather than DNA HI Vs require a host cell to reproduce and the hosts m humans are the T4 lymphocytes which are the cells primarily responsible for inducing the immune system to respond when provoked The HIV penetrates the cell wall of a T4 lymphocyte and deposits both its RNA and an enzyme called reverse transcriptase inside There the reverse transcriptase catalyzes the formation of a DNA strand that is complementary to the viral RNA The transcribed DNA then serves as the template from which the host lymphocyte produces copies of the virus which then leave the host to infect other T4 cells In the course of HIV reproduction the ability of the T4 lymphocyte to reproduce Itself IS compromised As the number of T4 cells decrease so does the body s ability to combat infections... 

Human Immunodeficiency Virus. Human immunodeficiency vims (HIV) causes Acquired Immunodeficiency Syndrome (AIDS), which has no cure. HIV infects the cells of the human immune system, such as T-lymphocytes, monocytes, and macrophages. After a long period of latency and persistent infection, it results in the progressive decline of the immune system, and leads to full-blown AIDS, resulting in death. 

Rossmann, M.G. Antiviral agents targeted to interact with viral capsid proteins and a possible application to human immunodeficiency virus. Proc. Natl. Acad. Sci. USA, 85 4625-4627, 1988. 

Human immunodeficiency virus type 1 (infection with) (Vol. 67 1996)... 

In patients infected with HIV (human immunodeficiency virus), the helper cell population is weakened to the point where the immune system is no longer able to function properly. The body thus becomes susceptible to otherwise nonlethal diseases such as pneumonia. 

M. A., Dorns, R. W., and Peiper, S. C. (1997). Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J. Virol. 71 6305-6314. 

Smyth, R. J., Yi, Y., Singh, A., and Collman, R. G. (1998). Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 isolate. J. Virol. 72 4478-4484. 

Ullum, H., Lepri, A. C., Victor, J., Aladdin, H., Phillips, A. N., Gerstoft, J., Skinhoj, P., and Pedersen, B. K. (1998). Production of beta-chemokines in human immunodeficiency virus (HIV) infection Evidence that high levels of macrophage in inflammatory protein-1-beta are asociated with a decreased risk of HIV progression. J. Infect. Dis. 177 331-336. 

Luciw P (1996) Human immunodeficiency viruses and their replication. In Fields BN, Knipe DN, Howley, PM (eds) Virology. Lippincott-Raven publishers, Philadelphia, PA, pp 1881-1952... 

Human immunodeficiency virus (HIV) (combined with other drugs)... 

The term generic indicates the drug is available in generic form. Gl, gastrointestinal HIV, human immunodeficiency virus. 

AIDS After considerable research, the causative agent for AIDS was identified as a virus, which was eventually named the Human Immunodeficiency Virus (HIV). 

Cooper OB, Brown TT, Dobs AS Opiate drug use a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 37(suppl 2) S132—S136, 2003... 

Luban J (2007) Cyclophihn A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol 81 1054-1061... 

Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase, J Virol 69 5087-5094... 

Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, BonhoefferS, Nowak MA, Hahn BH et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373 117-122... 

CarriUo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, Kempf DJ, Molla A (1998) In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 72 7532-7541 Chambers TJ, Nestorowicz A, Amberg SM, Rice CM (1993) Mutagenesis of the yellow fever virus NS2B protein effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. J Virol 67 6797-6807... 

---